Share This Post

Markets

Medtronic beats profit estimate on the strength of its cardio business

Medtronic beats profit estimate on the strength of its cardio business

Medical device maker Medtronic posted a better-than-expected quarterly profit on Tuesday, helped by higher sales in its top-selling cardiac and vascular unit, underpinning strength across its businesses.

Shares of the Dublin-based company rose 4 percent to $93.50 in premarket trading.

The cardiac and vascular unit that makes defibrillators, pace-makers, heart valves and stents raked in revenue of $2.81 billion, beating analysts’ estimate of $2.77 billion, according to Thomson Reuters I/B/E/S.

Evercore ISI analyst Vijay Kumar said all eyes were focused on Medtronic’s first-quarter print given the recent run in stock and the company came through solidly and beat the high end of expectations.

“What impressed us was the solid all-around performance across all the segments, and growth was balanced across geographies,” he added.

The company continues to expect full-year earnings to be in the range of $5.10 to $5.15 per share.

Net income attributable to Medtronic rose to $1.08 billion, or 79 cents per share, in the first quarter ended July 27, from $1.02 billion, or 74 cents per share, a year earlier.

Excluding items, it earned $1.17 per share, beating analysts’ expectations of $1.11 per share.

Net sales fell marginally to $7.38 billion, but still came above the average analyst estimate of $7.24 billion.

Share This Post

Leave a Reply